CN1530112A - Medicine for preventing fibrous liver and preparing method thereof - Google Patents
Medicine for preventing fibrous liver and preparing method thereof Download PDFInfo
- Publication number
- CN1530112A CN1530112A CNA031197590A CN03119759A CN1530112A CN 1530112 A CN1530112 A CN 1530112A CN A031197590 A CNA031197590 A CN A031197590A CN 03119759 A CN03119759 A CN 03119759A CN 1530112 A CN1530112 A CN 1530112A
- Authority
- CN
- China
- Prior art keywords
- extract
- salviae miltiorrhizae
- paeoniae rubra
- radix salviae
- hepatic fibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
An orally applied Chinese medicine in the form of tablet, particles, powder, capsule, or oral liquid for treating hepatic fibrosis is prepared from the extract of red sage root and the extract of red peony root in ratio of 7:3. Its preparing process is also disclosed.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of hepatic fibrosis, particularly use the medicine that Radix Salviae Miltiorrhizae extract and Radix Paeoniae Rubra extract prepare anti-hepatic fibrosis.
Background technology
Hepatic fibrosis is that hepatocyte necroses or during inflammatory stimulus, the paraplasm pathological change process of fibrous connective tissue in the liver, and various chronic hepatopathys such as viral hepatitis, alcoholic liver disease etc. all can develop into hepatic fibrosis, liver cirrhosis.Hepatitis is one of China's sickness rate disease with high, it is reported, hepatitis accounts for more than 10% of total population at the sickness rate of China.China is again the big country of drinking in the world, adds the change of environmental pollution and dietary structure, and at present, the sickness rate of hepatic fibrosis is in continuous rising, has now become one of problem that China hygiene department is concerned about, payes attention to most.In recent years, Chinese scholars has proposed a series of anti-hepatic fibrosis medicines and method to the formation mechanism of hepatic fibrosis, as the application corticoid, and treatments such as interferon, but the curative effect of these medicines can not be affirmed.Though have the treatment of Colchicum autumnale aspect anti-hepatic fibrosis to obtain certainly, it has bigger toxic and side effects, be difficult for taking for a long time.Chinese herbal medicine and preparation thereof are one of problems of domestic and international medical research unit primary study to the effect of anti-hepatic fibrosis always.In the recent period, China has begun to occur relevant compound recipe anti-hepatic fibrosis Chinese medicine preparation, as sunflower board liver-protecting tablet etc., but it is the big compound recipe crude preparation by using of Chinese medicine, and it is big to have a dose, and the cycle of taking is long, uncertain therapeutic efficacy is cut, treatment mechanism is difficult to shortcomings such as research, is difficult to deal with market anti-hepatic fibrosis patient's needs, more can't integrate with countries in the world.
Salviamiltiorrhizabung and Radix Paeoniae Rubra have certain blood circulation promoting and blood stasis dispelling, microcirculation improvement, increase liver blood flow amount, protect hepatocyte, alleviate hepatocellular degeneration, necrosis and inflammatory reaction, promote liver cell regeneration, suppress proliferation of fibrous tissue, suppress the hepatocyte lipid peroxidation, remove oxygen-derived free radicals, suppress collagenation and increase effect such as its decomposition.
The effective site Radix Salviae Miltiorrhizae extract of salviamiltiorrhizabung, it is the powder of being processed into through extraction separation by the dry root and rhizome of Labiatae Radix Salviae Miltiorrhizae (Salvia miltorrhiza Bunge), be the xanchromatic amorphous powder of a kind of palm fibre, gas is special, sour in the mouth, easily molten in water, methanol, ethanol, ethyl acetate.
Chinese medicine Radix Paeoniae Rubra is the dry rhizome of cohosh Radix Paeoniae (Paeonia lactflora Pall), the effective site Radix Paeoniae Rubra extract of Radix Paeoniae Rubra (Chishao Tiquwu) is processed into through extraction separation by the dry rhizome of Radix Paeoniae, be a kind of pale brown toner end, bitter in the mouth, easily molten in water, methanol, ethanol, ethyl acetate, insoluble in petroleum ether.
Utilize Radix Salviae Miltiorrhizae extract and Radix Paeoniae Rubra extract to make the medicine of anti-hepatic fibrosis, yet there are no report.
Summary of the invention
The purpose of this invention is to provide a kind of medicine of using Radix Salviae Miltiorrhizae extract and Radix Paeoniae Rubra extract preparation.
Particularly use the medicine that Radix Salviae Miltiorrhizae extract and Radix Paeoniae Rubra extract prepare anti-hepatic fibrosis.
Technical scheme of the present invention is:
Radix Salviae Miltiorrhizae extract and Radix Paeoniae Rubra extract prepare the medicine of anti-hepatic fibrosis, mainly the medicament of being made by following composition (composition by weight): 8～2 parts of Radix Salviae Miltiorrhizae extracts, 2～8 parts of Radix Paeoniae Rubra extracts; Preferred component proportioning is a Radix Salviae Miltiorrhizae extract: Radix Paeoniae Rubra extract=7: 3.
Radix Salviae Miltiorrhizae extract provided by the present invention and Radix Paeoniae Rubra extract prepare the medicine of anti-hepatic fibrosis, can add various pharmaceutically acceptable carriers when needing.
Radix Salviae Miltiorrhizae extract provided by the present invention and Radix Paeoniae Rubra extract prepare the medicine of anti-hepatic fibrosis, can be various peroral dosage forms, as various ways such as tablet, granule, powder, capsule, oral liquids.
Radix Salviae Miltiorrhizae extract provided by the present invention and Radix Paeoniae Rubra extract prepare the medicine of anti-hepatic fibrosis, can be capsule formulations, mainly make (composition by weight) by following component: 8～2 parts of Radix Salviae Miltiorrhizae extracts, 2～8 parts of Radix Paeoniae Rubra extracts, right amount of auxiliary materials.Adjuvant can select for use microcrystalline cellulose or corn starch or hydroxymethyl starch etc. to be fit to oral adjuvant.
The preparation method of anti-hepatic fibrosis medicines provided by the invention is as follows:
1, the preparation method of Radix Salviae Miltiorrhizae extract:
Get salvia piece, decocting boils secondary, adds doubly amount of water 10 (weight) for the first time, adds doubly amount of water 6 (weight) for the second time, and twice decoction each 1.5 hours filters respectively, discards medicinal residues, merges twice filtrate then, is concentrated into every milliliter of filtrate and contains crude drug 1.0g.Add 5% gelatin precipitation tannin in the filtrate after concentrating, placed 12 hours, filter, filtrate is concentrated into every milliliter and contains crude drug 1.5g, transfers PH2～3 with dilute hydrochloric acid, reuse equal-volume ethyl acetate extraction three times, merge ethyl acetate, the reclaim under reduced pressure ethyl acetate through 80 ℃ of vacuum dryings, promptly gets Radix Salviae Miltiorrhizae extract then.Containing radix salviae miltiorrhizae peimine in the Radix Salviae Miltiorrhizae extract must not calculate with radix salviae miltiorrhizae peimine sodium and is less than 10%; Containing the salvia-soluble total phenols must not calculate with protocatechualdehyde and is less than 60%.
2, the preparation method of Radix Paeoniae Rubra extract:
Get Radix Paeoniae Rubra and be ground into coarse powder, cross 20 mesh sieves, with 50% alcohol reflux secondary, reflux, extract, is doubly measured ethanol with 10 (weight) for the first time, reflux, extract, is doubly measured ethanol with 6 (weight) for the second time, each 1.5 hours, the extracting solution of merging secondary filtered, reduce pressure back and get ethanol, concentrated filtrate to relative density is 1.10 (60 ℃) then, adds hot water (≤90 ℃) dilution of triplication in concentrated solution, puts to add 5% gelatin water liquid after cold, making gelatin water liquid measure is 15% (w/w) of former concentrated solution, place after 24 hours, filter, (the post reducing was than 24: 1 by ZTC-1 type macroporous resin with filtrate then; Medical material is 4: 1 with the resin demand ratio; The absorption flow velocity is resin volume 2-3BV/ hour) negative with deionized water rinsing reducing sugar reaction to the eluent, reuse 40% ethanol elution, the eluent consumption is the 6BV of resin volume, the desorbing flow velocity is resin volume 1000.5-1BV/ hour, merge last twice ethanol elution, reduce pressure back once more and get ethanol, concentrate eluant to relative density is the thick extractum of 1.30～1.35 (50 ℃) then, through 80 ℃ of following vacuum dryings, promptly make Radix Paeoniae Rubra extract again.
3, Radix Salviae Miltiorrhizae extract provided by the present invention and Radix Paeoniae Rubra extract prepare the medicament capsule of anti-hepatic fibrosis, and its preparation method is:
Get Radix Salviae Miltiorrhizae extract and Radix Paeoniae Rubra extract in proportion, add appropriate amount of auxiliary materials, mixing is sieved, and with 80% ethanol wet granulation, incapsulates promptly after the drying.
The medicine that Radix Salviae Miltiorrhizae extract provided by the present invention and Radix Paeoniae Rubra extract prepare anti-hepatic fibrosis proves through pharmaceutical research and drug effect animal experiment result of study: the effective site Radix Salviae Miltiorrhizae extract of salviamiltiorrhizabung and Radix Paeoniae Rubra and Radix Paeoniae Rubra extract be proportioning by a certain percentage, picked-up and the decomposition of liver be can obviously increase, glutamate pyruvate transaminase, glutamic oxaloacetic transaminase, GOT rising suppressed hyaluronic acid, laminin; The same demonstration of animal pathological section has good preventive and therapeutic effect to hepatic fibrosis.Influence result of the test shown in table 1,2,3, Radix Salviae Miltiorrhizae extract to what cause the experimental rat hepatic fibrosis with carbon tetrachloride: the anti-liver dimension chemical fibre medicine of Radix Paeoniae Rubra extract=7: 3 has than remarkable influence hyaluronic acid (HA), laminin (LN); Radix Salviae Miltiorrhizae extract: the anti-hepatic fibrosis medicines of Radix Paeoniae Rubra extract=5: 5 or 3: 7 has significant difference to glutamic oxaloacetic transaminase, GOT (AST); The Radix Salviae Miltiorrhizae extract of each dosage and Radix Paeoniae Rubra extract anti-hepatic fibrosis medicines test group have appreciable impact to glutamate pyruvate transaminase (ALT) and hepatic tissue hydroxyproline, zoopery shows that hepatic fibrosis has good preventive and therapeutic effect to experimental rat for Radix Salviae Miltiorrhizae extract and Radix Paeoniae Rubra extract anti-hepatic fibrosis medicines.
Table 1: Radix Salviae Miltiorrhizae extract and Radix Paeoniae Rubra extract anti-hepatic fibrosis medicines
The influence that the experimental rat liver function is detected (X ± SE)
| Group | n | Glutamate pyruvate transaminase (ALT) | Glutamic oxaloacetic transaminase, GOT (AST) | Globulin (TP) | Albumin (ALB) |
| Normal group | 8 | ?61.65±15.24* | 159.84±37.14* | 62.94±4.00* | 27.06±2.10* |
| Model group | 9 | ?124.32±78.50 | 293.29±132.00 | 61.33±3.36 | 28.40±2.69 |
| The colchicine group | 8 | ?50.58±8.30* | 202.06±57.78 | 65.66±2.97 | 26.34±1.52 |
| Red 7: red 3 organize greatly | 8 | ?57.39±12.95* | 227.79±44.59 | 70,55±5.27 | 32.64±2.72 |
| Red 7: red 3 groups | 9 | ?57.18±13.53* | 245.58±53.98 | 64.10±5.59 | 29.77±2.44 |
| Red 5: red 5 organize greatly | 8 | ?50.28±10.54* | 163.51±38.61* | 65.10±4.00 | 29.79±2.10 |
| Red 5: red 5 groups | 8 | ?45.10±15.14* | 119.06±31.29* | 60.58±5.52 | 26.29±2.91 |
| Red 3: red 7 organize greatly | 8 | ?44.00±15.04* | 114.21±15.20* | 64.53±7.71 | 28.53± |
| Red 3: red 7 groups | 9 | ?53.73±14.76* | 152.23±27.13* | 63.64±5.96 | 28.22±3.11 |
Compare with model group: * P＜0.05
Table 2: Radix Salviae Miltiorrhizae extract and Radix Paeoniae Rubra extract anti-hepatic fibrosis medicines
To the influence of experimental rat hepatic fibrosis index of correlation (X ± SE)
| Group | n | Hyaluronic acid (HA) ng/ml | Laminin (LN) ug/l | Liver hydroxyproline ug/mgprot |
| Normal group | 8 | ?79.91±18.68* | 16.77±7.37* | 1.35±0.29* |
| Model group | 9 | ?155.14±57.12 | 29.92±12.20 | 2.56±0.70 |
| The colchicine group | 8 | ?97.27±23.98* | 16.06±10.68* | 1.61±0.40* |
| Red 7: red 3 organize greatly | 8 | ?96.14±33.34* | 15.73±6.33(#)* | 1.73±0.37* |
| Red 7: red 3 groups | 9 | ?94.50±32.48* | 6.69±2.01(#)* | 1.83±0.56* |
| Red 5: red 5 organize greatly | 8 | ?92.05±31.40* | 3.21±0.79(#)* | 1.78±0.70* |
| Red 5: red 5 groups | 8 | ?102.08±28.31* | 8.96±4.19(#)* | 1.87±0.35* |
| Red 3: red 7 organize greatly | 8 | ?111.99±37.87 | 17.93±9.46 | 1.85±0.61* |
| Red 3: red 7 groups | 9 | ?93.40±27.55* | 11.87±6.96* | 1.99±0.48 |
Compare with model group: * P＜0.05
Table 3: Radix Salviae Miltiorrhizae extract and Radix Paeoniae Rubra extract anti-hepatic fibrosis medicines
To experimental rat pathological observation result
| Group | Hepatic fibrosis | ||||||
| 0 grade | 1 grade | 2 grades | 3 grades | 4 grades | 5 grades | 6 grades | |
| Normal group | ???8 | ???0 | ???0 | ???0 | ???0 | ???0 | ???0 |
| Model group | ???0 | ???1 | ???2 | ???4 | ???1 | ???1 | ???0 |
| The colchicine group | ???0 | ???4 | ???7 | ???1 | ???0 | ???0 | ???0 |
| Red 7: red 3 organize greatly | ???2 | ???2 | ???7 | ???0 | ???0 | ???0 | ???0 |
| Red 7: red 3 groups | ???3 | ???6 | ???3 | ???0 | ???0 | ???0 | ???0 |
| Red 5: red 5 organize greatly | ???1 | ???2 | ???7 | ???0 | ???0 | ???0 | ???0 |
| Red 5: red 5 groups | ???1 | ???0 | ???9 | ???1 | ???0 | ???0 | ???0 |
| Red 3: red 7 organize greatly | ???0 | ???3 | ???7 | ???1 | ???0 | ???0 | ???0 |
| Red 3: red 7 groups | ???1 | ???2 | ???7 | ???0 | ???0 | ???0 | ???0 |
Learn check by statistics:
Model group: normal group x
2=11.22＞x
20.001 there is the difference of highly significant (l) P＜0.001 between model group and the normal group, show the modeling success.
Colchicine group: model group x
2=6.115＞x
20.05 (l) P＜0.05
Red red 73 organize greatly: model group x
2=6.960＞x
20.01 (l) P＜0.01
Red red 73 organize greatly: model group x
2=10.433＞x
20.01 (l) P＜0.01
Red red 55 organize greatly: model group x
2=6.110＞x
20.05 (l) P＜0.05
Red red 55 organize greatly: model group x
2=4.763＞x
20.05 (l) P＜0.05
Red red 37 organize greatly: model group x
2=4.287＞x
20.05 (l) P＜0.05
Red red 37 organize greatly: model group x
2=6.110＞x
20.05 (l) P＜0.05
This shows that each organizes medication therapy groups and Liver Fibrosis Model group, and all there were significant differences, illustrates that each dose compatibility of Radix Salviae Miltiorrhizae extract and Radix Paeoniae Rubra extract all has the positive therapeutic effect to hepatic fibrosis.Wherein no matter red 7: red 3 big small dose group is from pathological section itself or statistical testing of business cycles, and curative effect is all more obvious.
The present invention shows through acute toxicity animal experiment result of study, the medicine of the anti-hepatic fibrosis of Radix Salviae Miltiorrhizae extract and Radix Paeoniae Rubra extract preparation, and administration in selected dosage range has no side effect.
The invention has the advantages that: adopt effective ingredient in Chinese Radix Salviae Miltiorrhizae extract and Radix Paeoniae Rubra extract to research and develop out the novel drugs of treatment hepatic fibrosis, hepatic fibrosis had good preventive and therapeutic effect and effect, be an extremely promising new Chinese medicine, have positive meaning safeguarding people ' s health.
Specific embodiment
The preparation of embodiment 1, Radix Salviae Miltiorrhizae extract
(1) preparation of salvia miltiorrhiza raw material and pre-treatment:
Get the salviamiltiorrhizabung that the place of production is Luoyang, Henan, require to meet pertinent regulations under Radix Salviae Miltiorrhizae item of Chinese Pharmacopoeia version in 2000.After medical material is selected, gets clean medical material 50Kg and thinly slice, standby.
(2) preparation technology:
Get salvia piece 50Kg, decocting boils secondary, adds doubly amount of water 10 (weight) for the first time, adds doubly amount of water 6 (weight) for the second time, and twice decoction each 1.5 hours filters respectively, discards medicinal residues, merges twice filtrate then, is concentrated into every milliliter of filtrate and contains crude drug 1.0g.Add 5% gelatin precipitation tannin in the filtrate after concentrating, leak and placed 12 hours, filter, filtrate is concentrated into every milliliter and contains crude drug 1.5g, transfers PH2～3 with dilute hydrochloric acid, reuse equal-volume ethyl acetate extraction three times, merge ethyl acetate, the reclaim under reduced pressure ethyl acetate through 80 ℃ of vacuum dryings, promptly gets Radix Salviae Miltiorrhizae extract 1.285Kg then.This product contains radix salviae miltiorrhizae peimine and is calculated as 12.52% with radix salviae miltiorrhizae peimine sodium; Contain the salvia-soluble total phenols and be calculated as 82.79% with protocatechualdehyde.
The preparation of embodiment 2, Radix Paeoniae Rubra extract
(1) preparation of Radix Paeoniae Rubra raw material and pre-treatment:
Getting the place of production is the Chinese medicine Radix Paeoniae Rubra of Chifeng, the Inner Mongol, requires to meet pertinent regulations under Radix Paeoniae Rubra item of Chinese Pharmacopoeia version in 2000.Pulverizing Radix Paeoniae Rubra becomes coarse powder 25Kg standby.
(2) concrete preparation technology:
Get Radix Paeoniae Rubra coarse powder 25Kg, cross 20 mesh sieves, with 50% alcohol reflux secondary, reflux, extract, is measured ethanol with 10 times for the first time, reflux, extract, is measured ethanol with 6 times for the second time, each 1.5 hours, the extracting solution of merging secondary filtered, reduce pressure back and get ethanol, concentrated filtrate to relative density is 1.10 (60 ℃) then, adds hot water (≤90 ℃) dilution of triplication in concentrated solution, puts to add 5% gelatin water liquid after cold, making gelatin water liquid measure is 15% (w/w) of former concentrated solution, place after 24 hours, filter when reaching below 10 ℃, (the post reducing was than 24: 1 by ZTC-1 type macroporous resin with filtrate then; Medical material is 4: 1 with the resin demand ratio; The absorption flow velocity is resin volume 2-3BV/ hour) negative with deionized water rinsing reducing sugar reaction to the eluent, reuse 40% ethanol elution, the eluent consumption is the 6BV of resin volume, the desorbing flow velocity is resin volume 1000.5-1BV/ hour, merge last twice ethanol elution, reduce pressure back once more and get ethanol, concentrate eluant to relative density is the thick extractum of 1.30～1.35 (50 ℃) then, through 80 ℃ of following vacuum dryings, promptly make Radix Paeoniae Rubra extract 0.962Kg again.This product contains peoniflorin 54.26%; Contain the Radix Paeoniae Rubra phenolic acid and be calculated as 8.39% with gallic acid.
Embodiment 3, Radix Salviae Miltiorrhizae extract and Radix Paeoniae Rubra extract prepare the anti-hepatic fibrosis medicines capsule
(1) component proportioning:
Radix Salviae Miltiorrhizae extract 77g
Radix Paeoniae Rubra extract 33g
Microcrystalline cellulose 140g
Make 1000 of capsules altogether.
(2) component proportioning:
Above-mentioned prescription raw material blending is sieved,, incapsulate after the drying and get final product with 80% ethanol wet granulation.
Embodiment 4, Radix Salviae Miltiorrhizae extract and Radix Paeoniae Rubra extract prepare the anti-hepatic fibrosis medicines capsule
(1) component proportioning:
Radix Salviae Miltiorrhizae extract 55g
Radix Paeoniae Rubra extract 55g
Corn starch 140g
Make 1000 of capsules altogether.
(2) preparation method: with embodiment 3.
Embodiment 5, Radix Salviae Miltiorrhizae extract and Radix Paeoniae Rubra extract prepare the anti-hepatic fibrosis medicines capsule
(1) component proportioning:
Radix Salviae Miltiorrhizae extract 33g
Radix Paeoniae Rubra extract 77g
Hydroxymethyl starch 140g
Make 1000 of capsules altogether.
(2) preparation method: with embodiment 3.
Claims (6)
1, a kind of medicine of anti-hepatic fibrosis is characterized in that described anti-hepatic fibrosis medicines is the medicament of mainly being made by following proportioning components (composition by weight): 8～2 parts of Radix Salviae Miltiorrhizae extracts, 2～8 parts of Radix Paeoniae Rubra extracts.
2, medicine according to claim 1 is characterized in that the medicament (composition by weight) that described anti-hepatic fibrosis medicines is mainly made by following proportioning components: 7 parts of Radix Salviae Miltiorrhizae extracts, 3 parts of Radix Paeoniae Rubra extracts.
3, medicine according to claim 1 and 2 is characterized in that described anti-hepatic fibrosis medicament, can be various peroral dosage forms.
4, medicine according to claim 1 and 2 is characterized in that described anti-hepatic fibrosis medicament, can be capsule formulation, is made by following component: Radix Salviae Miltiorrhizae extract 77g, and Radix Paeoniae Rubra extract 33g, adjuvant 140g makes 1000 of capsules altogether.
5, medicine according to claim 4 is characterized in that described adjuvant can be microcrystalline cellulose or other suitable oral adjuvant such as corn starch or hydroxymethyl starch.
6, prepare the method for the described anti-hepatic fibrosis medicines of claim 1, comprise the steps:
A, the preparation of Radix Salviae Miltiorrhizae extract: get salvia piece, decocting boils secondary, add for the first time 10 times of amounts of water, add for the second time 6 times of amounts of water, twice decoction each 1.5 hours filters respectively, discards medicinal residues, merge twice filtrate then, be concentrated into every milliliter of filtrate and contain crude drug 1.0g, add 5% gelatin precipitation tannin in the filtrate after concentrating, placed 12 hours, filter, filtrate is concentrated into every milliliter and contains crude drug 1.5g, transfers PH2～3 with dilute hydrochloric acid, reuse equal-volume ethyl acetate extraction three times, merge ethyl acetate, the reclaim under reduced pressure ethyl acetate through 80 ℃ of vacuum dryings, promptly gets Radix Salviae Miltiorrhizae extract then, contain radix salviae miltiorrhizae peimine in the Radix Salviae Miltiorrhizae extract and must not calculate with radix salviae miltiorrhizae peimine sodium and be less than 10%, contain the salvia-soluble total phenols and must not calculate with protocatechualdehyde and be less than 60%;
B, the preparation of Radix Paeoniae Rubra extract: get Radix Paeoniae Rubra and be ground into coarse powder, cross 20 mesh sieves, with 50% alcohol reflux secondary, reflux, extract, is measured ethanol with 10 times for the first time, reflux, extract, is measured ethanol with 6 times for the second time, each 1.5 hours, the extracting solution that merges secondary, filter, reduce pressure back and get ethanol, concentrated filtrate to relative density is 1.10 (60 ℃) then, in concentrated solution, add hot water (≤90 ℃) dilution of triplication, put and add 5% gelatin water liquid after cold, making gelatin water liquid measure is 15% (w/w) of former concentrated solution, place after 24 hours, filter, then that filtrate is negative with deionized water rinsing reducing sugar reaction to the eluent by macroporous resin (the post reducing is than 24: 1, and medical material is 4: 1 with the resin demand ratio, adsorb flow velocity be resin volume 2-3BV/ hour), reuse 40% ethanol elution, the eluent consumption is the 6BV of resin volume, and the desorbing flow velocity is resin volume 1000.5-1BV/ hour, merges last twice ethanol elution, reduce pressure back once more and get ethanol, concentrate eluant to relative density is the thick extractum of 1.30～1.35 (50 ℃) then, through 80 ℃ of following vacuum dryings, promptly makes Radix Paeoniae Rubra extract again;
C, Radix Salviae Miltiorrhizae extract and the capsular preparation of Radix Paeoniae Rubra extract anti-hepatic fibrosis medicines: get 8～2 parts of Radix Salviae Miltiorrhizae extracts, 2～8 parts of Radix Paeoniae Rubra extracts add right amount of auxiliary materials, mixing sieves, with 80% ethanol wet granulation, incapsulate after the drying, promptly get the anti-hepatic fibrosis medicines capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03119759 CN1283258C (en) | 2003-03-11 | 2003-03-11 | Medicine for preventing fibrous liver and preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03119759 CN1283258C (en) | 2003-03-11 | 2003-03-11 | Medicine for preventing fibrous liver and preparing method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1530112A true CN1530112A (en) | 2004-09-22 |
| CN1283258C CN1283258C (en) | 2006-11-08 |
Family
ID=34285251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03119759 Expired - Fee Related CN1283258C (en) | 2003-03-11 | 2003-03-11 | Medicine for preventing fibrous liver and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1283258C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103191186A (en) * | 2012-01-04 | 2013-07-10 | 天士力制药集团股份有限公司 | Application of salvia miltiorrhiza preparation in preparing anti-liver-fibrosis medicines |
| CN104800776A (en) * | 2015-05-19 | 2015-07-29 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating alcoholic hepatic fibrosis |
| CN111419912A (en) * | 2020-03-21 | 2020-07-17 | 北京中医药大学 | Red peony root polyphenol pharmaceutical preparation for treating acute hepatitis and preparation method thereof |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7011600B2 (en) | 2003-02-28 | 2006-03-14 | Fallbrook Technologies Inc. | Continuously variable transmission |
| DK1815165T3 (en) | 2004-10-05 | 2012-06-18 | Fallbrook Technologies Inc | Infinitely variable transmission |
| US7632203B2 (en) | 2005-10-28 | 2009-12-15 | Fallbrook Technologies Inc. | Electromotive drives |
| PL1954959T3 (en) | 2005-11-22 | 2013-10-31 | Fallbrook Ip Co Llc | Continuously variable transmission |
| KR101317329B1 (en) | 2005-12-09 | 2013-10-15 | 폴브룩 테크놀로지즈 인크 | Continuously variable transmission |
| US7882762B2 (en) | 2006-01-30 | 2011-02-08 | Fallbrook Technologies Inc. | System for manipulating a continuously variable transmission |
| EP2038531A4 (en) | 2006-06-26 | 2012-01-25 | Fallbrook Technologies Inc | Continuously variable transmission |
| US8376903B2 (en) | 2006-11-08 | 2013-02-19 | Fallbrook Intellectual Property Company Llc | Clamping force generator |
| US8738255B2 (en) | 2007-02-01 | 2014-05-27 | Fallbrook Intellectual Property Company Llc | Systems and methods for control of transmission and/or prime mover |
| WO2008100792A1 (en) | 2007-02-12 | 2008-08-21 | Fallbrook Technologies Inc. | Continuously variable transmissions and methods therefor |
| CN103438207B (en) | 2007-02-16 | 2016-08-31 | 福博科技术公司 | Unlimited speed changing type buncher, buncher and method, assembly, sub-component and parts |
| CN101720397B (en) | 2007-04-24 | 2013-01-02 | 福博科技术公司 | Electric traction drives |
| CN103697120B (en) | 2007-07-05 | 2017-04-12 | 福博科技术公司 | Continuously variable transmission |
| WO2009065055A2 (en) | 2007-11-16 | 2009-05-22 | Fallbrook Technologies Inc. | Controller for variable transmission |
| CA2708634C (en) | 2007-12-21 | 2017-08-01 | Fallbrook Technologies Inc. | Automatic transmissions and methods therefor |
| CA2942806C (en) | 2008-02-29 | 2018-10-23 | Fallbrook Intellectual Property Company Llc | Continuously and/or infinitely variable transmissions and methods therefor |
| CN107246463A (en) | 2008-06-23 | 2017-10-13 | 福博科知识产权有限责任公司 | Buncher |
| WO2010017242A1 (en) | 2008-08-05 | 2010-02-11 | Fallbrook Technologies Inc. | Methods for control of transmission and prime mover |
| US8469856B2 (en) | 2008-08-26 | 2013-06-25 | Fallbrook Intellectual Property Company Llc | Continuously variable transmission |
| US8167759B2 (en) | 2008-10-14 | 2012-05-01 | Fallbrook Technologies Inc. | Continuously variable transmission |
| WO2010120933A1 (en) | 2009-04-16 | 2010-10-21 | Fallbrook Technologies Inc. | Stator assembly and shifting mechanism for a continuously variable transmission |
| US8512195B2 (en) | 2010-03-03 | 2013-08-20 | Fallbrook Intellectual Property Company Llc | Infinitely variable transmissions, continuously variable transmissions, methods, assemblies, subassemblies, and components therefor |
| US8888643B2 (en) | 2010-11-10 | 2014-11-18 | Fallbrook Intellectual Property Company Llc | Continuously variable transmission |
| AU2012240435B2 (en) | 2011-04-04 | 2016-04-28 | Fallbrook Intellectual Property Company Llc | Auxiliary power unit having a continuously variable transmission |
-
2003
- 2003-03-11 CN CN 03119759 patent/CN1283258C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103191186A (en) * | 2012-01-04 | 2013-07-10 | 天士力制药集团股份有限公司 | Application of salvia miltiorrhiza preparation in preparing anti-liver-fibrosis medicines |
| CN104800776A (en) * | 2015-05-19 | 2015-07-29 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating alcoholic hepatic fibrosis |
| CN111419912A (en) * | 2020-03-21 | 2020-07-17 | 北京中医药大学 | Red peony root polyphenol pharmaceutical preparation for treating acute hepatitis and preparation method thereof |
| CN111419912B (en) * | 2020-03-21 | 2022-05-13 | 北京中医药大学 | Red peony root polyphenol pharmaceutical preparation for treating acute hepatitis and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1283258C (en) | 2006-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1283258C (en) | Medicine for preventing fibrous liver and preparing method thereof | |
| CN1413724A (en) | Brain active effect matter for prevention and curing encephalopathy and developing intelligence and its preparation method | |
| WO2016127463A1 (en) | Medicine for protecting the liver, removing toxins, reducing blood lipids and reducing blood sugar and use thereof | |
| CN1839944A (en) | Granular composition for reducing blood fat and process for producing the same | |
| CN100534508C (en) | Method for extracting effective sites group of smilax China root | |
| CN1069542C (en) | Medicine for treating chronic hepatism and its preparing process | |
| CN1166388C (en) | Medicine for treating nosal inflammation | |
| CN1895623A (en) | Medicinal composition for treating fatty liver, its preparation and use | |
| CN103933195B (en) | A kind of Chinese medicine composition and preparation prevent and treat the application in hepatopathy medicine | |
| CN1927324A (en) | Preparation method of traditional medicine preparation for treating women's menoxenia | |
| CN1155592C (en) | Process for preparing total jujuboflavone with calmative and hypnosis action | |
| CN1730090A (en) | Chinese traditional medicinal composition for treating hepatitis and process for preparing the same | |
| CN1369306A (en) | 'Huajuhong' preparation and its preparing process | |
| CN101385783A (en) | Huganning tablets for treating chronic and urgent liver disease and preparation method thereof | |
| CN1216613C (en) | Health-care product capable of regulating blood-lipid and its preparation method | |
| CN1899574A (en) | Chinese medicine composition for preventing and controlling liver cancer and its use | |
| CN1887316A (en) | Chinese medicine composition and its prepn process and application | |
| CN1895477A (en) | Antidespressant and its preparation | |
| CN1814153A (en) | Medicine composition for preventing and treating breast cancer and preparing method | |
| CN1857630A (en) | Proteinuria treating Chinese medicine and its preparing method and use | |
| CN1470271A (en) | Chinese medicinal compound preparation for treating liver fibrillation disease and its preparation method | |
| CN1268362A (en) | Compound Chinese herb medicine for curing fibrosis of liver and hepatocirrhosis and its preparation method | |
| CN1660282A (en) | Combination of medication for treating hepatitis B and preparation method | |
| CN1360902A (en) | Blood lipoid regulating medicine and its prepn | |
| CN1814250A (en) | Chinese medicine composition for treating liver cirrhosis ascites and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING INTERNATIONAL BIOLOGY PRODUCTS INSTITUTE Free format text: FORMER OWNER: JINQIAO SHIDAI BIOMEDICAL RESEARCH DEVELOPMENT CENTER, BEIJING Effective date: 20070316 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20070316 Address after: 100086 No. 42, Zhongguancun Avenue, Haidian District, Beijing Patentee after: Beijing International Biological Products Research Institute Co Ltd Address before: 100086 No. 42, Zhongguancun Avenue, Haidian District, Beijing Patentee before: Jinqiao Shidai Biological Medicine Research and Development Center, Beijing |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061108 Termination date: 20180311 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |